MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.
MYR GmbH Announces 10 million $ Financing Round After Successful Clinical Phase 2a
Further product development to combat hepatitis delta virus infection received a boost today thanks to commitments from MYR GmbH investors Maxwell Biotech Venture Fund and High-Tech Gruenderfonds. The combined investment of 7.9 million Euro (approximately $10 million) will be used by MYR for further development of…
Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program
Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds Maxwell Biotech Venture Fund (MBVF), founded with the participation of the Russian Government’s Russian Venture Company, announced today its first investment involving the High-Tech Gründerfonds (HTGF), one of…
High-Tech Gründerfonds invests in a novel Hepatits B compound
German Biotech MYR GmbH develops the viral entry inhibitor Myrcludex, a so-called „first-in-class“ drug for the treatment of chronic hepatitis B and D infections. The HTGF investment of 500,000 € enables the start of Phase 1 of clinical development already in summer 2011. MYR develops its lead compound in close…
21. Jan 2011